ArticleAsian Pacific journal of cancer prevention : APJCP2025
Effect of Alpha1 Antitrypsin on PD-1/PD-L1 and EGFR in Colitis-Associated Colorectal Cancer BALB/c Mouse Model
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate whether Human alpha-1 antitrypsin affects Programmed cell death protein 1 (PD-1) and its ligand (PD-L1) as well as epidermal growth factor receptor (EGFR) expression using a colon cancer tissues in chemically induced colorectal cancer (CRC) model. Previous study indicated a protective role of AAT administration on the development of cancer in CRC mouse model. METHODOLOGY: The expression of PD1/PDL1 and EGFR were analyzed in colon cancer tissue collected from (AOM/DSS) CRC mice using both real time gene expression (qPCR) and immunohistochemistry(IHC).
resultsStudy results showed that AAT treatment reduced PD-L1 protein expression by 63.5% (mean H score: 7.8±1.3 to 2.85±0.85, p=0.0004) and EGFR protein expression by 48.9% (mean H score: 1.78±0.76 to 0.91±0.60, p=0.04) in the tissue of AOM/DSS-treated mice. In addition, AAT treatment controlled PD1 gene expression and repressed EGFR gene expression by 1.4-fold compared to DSS samples. Immunohistochemical analysis revealed various degrees of PD1 protein expression, and CD4 and CD8 positive lymphocytes were found in the tumor microenvironment.
conclusionThese findings suggest that AAT treatment has immunomodulatory properties and may represent a promising therapeutic strategy for colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.